Study S000342

A Phase 1 Clinical Trial to Assess the Safety of DWRX5003 and Relative Bioavailability to DWC202502 and DWC202503 in Healthy Adult Volunteers

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07539415
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: DOUBLE
Status: RECRUITING
Enrollment: 72
Start: 2026-05-06
Primary completion: 2026-10-27
Lead sponsor: Daewoong Pharmaceutical Co. LTD.
Conditions: Obesity & Overweight; Type 2 Diabetes
Interventions: DRUG:DWRX5003; DRUG:DWC202502; DRUG:DWC202503; OTHER:DWRX5003P
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

AUC 0-t [Pre-dose (0 hour) up to 672 hours post-dose]
Cmax [Pre-dose (0 hour) up to 672 hours post-dose]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.